Literature DB >> 28003818

Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma.

Yucel Altundal1, Erno Sajo1, G Mike Makrigiorgos2, Ross I Berbeco2, Wilfred Ngwa3.   

Abstract

This work investigates the dosimetric feasibility of employing gold nanoparticles (AuNPs) or carboplatin nano-particles (CNPs) to enhance radiotherapy (RT) treatment efficacy for ocular cancers: retinoblastoma (Rb) and choroidal melanoma (CM), during kV-energy internal and external beam radiotherapy. The results predict that substantial dose enhancement may be achieved by employing AuNPs or CNPs in conjunction with radiotherapy for ocular cancer using kV-energy photon beams. Brachytherapy sources yield higher dose enhancement than the external beam in kV energy range. However, the external beam has the advantage of being non-invasive.

Entities:  

Keywords:  Choroidal Meanoma; Dose Enhancement; Nanoparticles; Retinoblastoma

Year:  2015        PMID: 28003818      PMCID: PMC5166600          DOI: 10.1007/978-3-319-19387-8_221

Source DB:  PubMed          Journal:  IFMBE Proc        ISSN: 1680-0737


  19 in total

1.  Localized dose enhancement to tumor blood vessel endothelial cells via megavoltage X-rays and targeted gold nanoparticles: new potential for external beam radiotherapy.

Authors:  Ross I Berbeco; Wilfred Ngwa; G Mike Makrigiorgos
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-12-14       Impact factor: 7.038

Review 2.  Challenges and obstacles of ocular pharmacokinetics and drug delivery.

Authors:  Arto Urtti
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

3.  Brachytherapy and endoresection for choroidal melanoma: a cohort study.

Authors:  James C Rice; Clare Stannard; Colin Cook; Karin Lecuona; Landon Myer; Raoul P Scholtz
Journal:  Br J Ophthalmol       Date:  2013-10-16       Impact factor: 4.638

4.  Implications on clinical scenario of gold nanoparticle radiosensitization in regards to photon energy, nanoparticle size, concentration and location.

Authors:  E Lechtman; N Chattopadhyay; Z Cai; S Mashouf; R Reilly; J P Pignol
Journal:  Phys Med Biol       Date:  2011-07-06       Impact factor: 3.609

5.  A stochastic model of cell survival for high-Z nanoparticle radiotherapy.

Authors:  Piotr Zygmanski; Wolfgang Hoegele; Panagiotis Tsiamas; Fulya Cifter; Wil Ngwa; Ross Berbeco; Mike Makrigiorgos; Erno Sajo
Journal:  Med Phys       Date:  2013-02       Impact factor: 4.071

6.  Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.

Authors:  Shin J Kang; Chandrasekar Durairaj; Uday B Kompella; Joan M O'Brien; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2009-08

Review 7.  Developments in the management of uveal melanoma.

Authors:  Bertil Damato
Journal:  Clin Exp Ophthalmol       Date:  2004-12       Impact factor: 4.207

Review 8.  Retinoblastoma: saving life with vision.

Authors:  David H Abramson
Journal:  Annu Rev Med       Date:  2014       Impact factor: 13.739

9.  Recurrent renal salt wasting in a child treated with carboplatin and etoposide.

Authors:  C Tscherning; H Rubie; A Chancholle; S Claeyssens; A Robert; J Fabre; F Bouissou
Journal:  Cancer       Date:  1994-03-15       Impact factor: 6.860

10.  Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose.

Authors:  Justin Hanlon; Choonsik Lee; Erik Chell; Michael Gertner; Steven Hansen; Roger W Howell; Wesley E Bolch
Journal:  Med Phys       Date:  2009-08       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.